While the use of radioimmunotherapy for lymphoma increases, the feasibility and efficacy of autologous stem cell transplant for subsequent relapse remains unknown. We report a 48-year-old male with transformed follicular mixed non-Hodgkin's lymphoma. There is increasing use of radiolabelled antibody therapy in non-Hodgkin's lymphoma (NHL), especially in the follicular subtype, although there is limited information available about delayed toxicities. The targeted nature of this therapy may limit radiation exposure to vital organs, but the possibility of damage to bone marrow stem cells is of concern. Potentially, this could preclude autologous stem cell transplantation, an established treatment for relapsed NHL. We report for the first time a patient, having previously received two courses of radioimmunotherapy, undergoing successful peripheral blood stem cell transplantation (PBSCT) with radiation-based conditioning for relapsed NHL without unexpected toxicity.
There is increasing use of radiolabelled antibody therapy in non-Hodgkin's lymphoma (NHL), especially in the follicular subtype, although there is limited information available about delayed toxicities. The targeted nature of this therapy may limit radiation exposure to vital organs, but the possibility of damage to bone marrow stem cells is of concern. Potentially, this could preclude autologous stem cell transplantation, an established treatment for relapsed NHL. We report for the first time a patient, having previously received two courses of radioimmunotherapy, undergoing successful peripheral blood stem cell transplantation (PBSCT) with radiation-based conditioning for relapsed NHL without unexpected toxicity. 
Case report
In March 1988, at the age of 35 years, this previously well male presented with generalized lymphadenopathy. He had an excision biopsy of a right axillary node. Stage IV-A follicular mixed cell (small cleaved and large cell) NHL was diagnosed. He was initially treated with a total of 10 cycles of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD), interrupted after the fourth cycle due to pneumocystis pneumonia. CT scans and physical examination at the completion of therapy showed no evidence of disease, but bone marrow involvement persisted.
In January 1990, he developed new lymphadenopathy, which slowly increased in size. In December 1991, he had an inguinal node biopsy, which again showed follicular mixed cellularity/follicular large cell lymphoma. From February to June 1992 he received six cycles of cyclophosphamide, vincristine and prednisone (CVP). Due to significant disease progression, he was then given four cycles of dexamethasone, high-dose cytarabine and cisplatin (DHAP), with partial response.
In June 1994, with increasing lymphadenopathy and bulky disease, he was entered on a phase I/II trial of radioimmunotherapy with iodine 131 I tositumomab (anti-CD20/Bexxar; Corixa, Seattle, WA, USA and GlaxoSmithKline, Research Triangle Park, NC, USA) at the University of Michigan. He was treated with the maximally tolerated dose (75 cGy to total body, 103 mCi) and achieved a complete remission. He relapsed in August 1997 with bulky disease and an elevated LDH, without evidence of lymphoma on bone marrow biopsy, and was given a second maximally tolerated dose of the radiolabeled antibody without response. He then received high-dose dexamethasone in October 1997. In December 1997 he had persisting lymphadenopathy, and a left inguinal node biopsy revealed transformation to diffuse large cell NHL. He then received three courses of methotrexate, ifosphamide, mitoxantrone and etoposide (MINE).
In January 1998, his bone marrow was negative for disease, but an 8 ϫ 3 cm retroperitoneal mass persisted. Bone marrow studies were performed (bilateral posterior iliac spine sampling) on 14 April 1998 with no evidence of lymphoma on morphology or flow cytometry. The cellularity was 70-80%, with trilineage hematopoiesis and normal maturation.
He then received high-dose cyclophosphamide (7 g/m 2 ) followed by G-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA 900 g daily) with successful collection of peripheral blood stem cells (total CD34 + cells of 4.36 ϫ 10 6 /kg, in six pheresis collections). He underwent conditioning with total body irradiation (hyperfractionated: total dose 1200 cGy), cyclophosphamide (100 mg/kg based on ideal weight) and etoposide (60 mg/kg on actual body weight) prior to autologous stem cell transplantation on 29 April 1998. He had prompt engraftment, with the absolute neutrophil count greater than 0.5 ϫ 10 9 /l on day +10, and the unsupported platelet count greater than 20 ϫ 10 12 /l on day +12 (30 ϫ 10 12 /l on day +15). There was no significant hepatic, pulmonary or other organ toxicity post transplant.
On day +32, he commenced a course of IL-2 as per the ongoing SWOG study 9438 (induction: 9.0 IU/m 2 /24 h continuous infusion for 4 days (days 1-4) as an inpatient. He then received a maintenance of 1.6 IU/m 2 /24 h continuous infusion for 9 days (days 9-18) as an outpatient). This was well tolerated, with only mild fever, diarrhea and erythema.
A repeat CT scan 3 months post transplant showed minimal residual disease in the retroperitoneum and abdomen, with no masses or lymphadenopathy. There was no evidence of lymphoma on clinical evaluation.
There has been no evidence of disease progression since transplant, with regular clinical assessments, blood tests and CT scans. 
Discussion
Histologic progression of follicular lymphoma is accompanied by a marked worsening of prognosis, with historically a median survival of less than 12 months from the time of diagnosis. 1 Aggressive combination chemotherapy can result in complete remission in some cases, although resistance to alkylating agent therapy may be associated with its prior use. 1 Other current available strategies include the use of high-dose therapy and autologous stem cell transplantation, which has been reported to have high complication rates though a suggested benefit over standard chemotherapy.
2 A more recent case-matched study from the EBMTR found no significant difference in overall survival for transformed follicular disease compared to lowgrade or de novo high-or intermediate-grade NHL. 3 This supports the use of high-dose therapy in this group.
Recently, the novel therapy of radiolabelled immunotherapy has shown great promise. [4] [5] [6] [7] In the development of effective treatments for NHL, the results of therapy have been compromised by early and late toxicities, including secondary bone marrow dysfunction.
Alkylating agents cause characteristic unbalanced chromosomal aberrations including the loss of all or part of chromosomes 5 or 7, and usually have a long latency period before progression to leukemia. 8 Topoisomerase inhibitors are associated with multiple DNA strand breaks with resolution by chromosomal translocation including chromosome 11 band q23. 8 A recent retrospective case-control study of myelodysplasia/leukemia post autograft for NHL or Hodgkin's disease 9 found that the conditioning regimens including total body irradiation (TBI) at doses Ͻ12 Gy did not appear to have elevated risks (12 Gy was given in this reported case). However, these risks were elevated with higher doses of radiotherapy. 9 The major risk for secondary leukemia in HD and NHL is the use of alkylating agents included in the pre-transplant chemotherapy schedule. 9 In post-autograft MDS, the largest contributor to the secondary marrow disorders was pretransplant chemotherapy including chlorambucil and mechlorethamine (eg MOPP-like regimens), with increased risks associated with higher doses/longer duration of therapy. 9 Other studies also suggest that the pre-autograft chemotherapy and radiation, rather than the high-dose therapy itself, have a cumulative leukemogenic role in the development of these secondary marrow disorders. 10 The risks for AML/MDS following autologous stem cell transplant have been reported to be up to 18% in some early series. 11 However, more recent studies with the EBMT analysis of registry data containing large numbers of transplanted patients show the risks are significantly lower, being 3% at 5 years for NHL autograft patients. 12 The introduction of radioimmunotherapy such as the anti-CD20 iodine 131 I tositumomab (Bexxar) has been associated with concerns regarding marrow toxicity, particularly in patients with bone marrow disease involvement. This includes potential bone marrow dysfunction causing cytopenias and damage to stem cells resulting in myelodysplasia. Also, the collection of normally functioning stem cells for possible autologous stem cell transplantation may be compromised. In the long-term follow-up of 59 patients with chemotherapy-relapsed/refractory NHL receiving iodine 131 I tositumomab, myelodysplasia developed in five (8.4%). 5 Also, solid tumors have been reported in this group. As detailed above, this may be related solely to prior therapies including alkylating agents and not necessarily to the radioimmunotherapy. Iodine 131 I tositumomab has been used with high response rates as single agent therapy for relapsed /refractory B cell NHL. This includes low-grade and transformed low-grade B cell NHLs, 5, 6 as in this case. The targeted nature of this therapy is highly likely to limit toxicity to radiosensitive organs other than the bone marrow. Encouragingly, high dose iodine 131 I tositumomab (Bexxar) has been used with or without etoposide and cyclophosphamide as conditioning for autologous stem cell transplantation for relapsed B cell lymphomas, with favorable overall and disease-free survival. 4 This case highlights the ability to mobilize stem cells after iodine 131 I tositumomab (Bexxar), even two courses, in a patient who had been heavily pre-treated with chemotherapy. Also, it may be possible to give high-dose chemoradiotherapy after radioimmunotherapy without excessive toxicity and, given the benefit to our patient, this strategy can be considered in similar patients.
